铂-话题@MedSci

#铂#

382篇内容 | 6092人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1737755, encodeId=ae001e3775529, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Clin Cancer Res：Adavosertib联合化疗治疗铂耐药的卵巢癌、输卵管癌及腹膜癌的效果, objectType=article, longId=221499, objectId=28ce221499a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28ce221499a5, replyNumber=0, likeNumber=141, createdTime=2022-07-02, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28ce221499a5, moduleTitle=Clin Cancer Res：Adavosertib联合化疗治疗铂耐药的卵巢癌、输卵管癌及腹膜癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28ce221499a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737760, encodeId=01131e37760ef, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=JAMA Netw Open：中肿麦海强教授团队证实奈达铂为基础的同期放化疗可作为II-IVB期鼻咽癌患者的有效治疗方案, objectType=article, longId=292561, objectId=7ac929256113, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ac929256113, replyNumber=0, likeNumber=72, createdTime=2022-09-20, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ac929256113, moduleTitle=JAMA Netw Open：中肿麦海强教授团队证实奈达铂为基础的同期放化疗可作为II-IVB期鼻咽癌患者的有效治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ac929256113)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737799, encodeId=8bac1e37799f1, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Clin Oncol：卡培他滨加用奥沙利铂可作为II-III期结直肠癌的替代辅助治疗, objectType=article, longId=731074, objectId=f8d8e3107483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8d8e3107483, replyNumber=0, likeNumber=105, createdTime=2023-04-03, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8d8e3107483, moduleTitle=J Clin Oncol：卡培他滨加用奥沙利铂可作为II-III期结直肠癌的替代辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8d8e3107483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737758, encodeId=592f1e37758d5, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=BMC Cancer：顺铂加依托泊苷(EP) vs卡铂加依托泊苷(EC)治疗广泛期SCLC的疗效和安全性, objectType=article, longId=291846, objectId=80082918465c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80082918465c, replyNumber=0, likeNumber=94, createdTime=2022-03-20, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80082918465c, moduleTitle=BMC Cancer：顺铂加依托泊苷(EP) vs卡铂加依托泊苷(EC)治疗广泛期SCLC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80082918465c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737790, encodeId=f45e1e377908e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=JAMA Oncol：紫杉醇+顺铂+卡培他滨诱导化疗可改善晚期鼻咽癌患者的生存预后, objectType=article, longId=302272, objectId=31553022e20d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31553022e20d, replyNumber=0, likeNumber=74, createdTime=2022-11-16, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31553022e20d, moduleTitle=JAMA Oncol：紫杉醇+顺铂+卡培他滨诱导化疗可改善晚期鼻咽癌患者的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31553022e20d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737748, encodeId=58ec1e37748de, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=奥沙利铂联合多烯磷脂酰胆碱对胃癌细胞增殖影响研究, objectType=article, longId=221039, objectId=7a5222103931, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a5222103931, replyNumber=0, likeNumber=63, createdTime=2022-01-14, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a5222103931, moduleTitle=奥沙利铂联合多烯磷脂酰胆碱对胃癌细胞增殖影响研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a5222103931)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737782, encodeId=d8fd1e37782cb, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Ther Adv Med Oncol：依维莫司联合顺铂治疗晚期肺外神经内分泌癌(EP-NEC)的疗效和安全性, objectType=article, longId=300077, objectId=1a413000e765, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a413000e765, replyNumber=0, likeNumber=67, createdTime=2023-01-09, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a413000e765, moduleTitle=Ther Adv Med Oncol：依维莫司联合顺铂治疗晚期肺外神经内分泌癌(EP-NEC)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a413000e765)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737740, encodeId=f1d71e37740d2, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌, objectType=article, longId=220113, objectId=b4a822011305, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4a822011305, replyNumber=0, likeNumber=82, createdTime=2021-12-22, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4a822011305, moduleTitle=Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4a822011305)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737757, encodeId=f0771e3775738, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌, objectType=article, longId=221752, objectId=5171221e521f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5171221e521f, replyNumber=0, likeNumber=96, createdTime=2022-10-11, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5171221e521f, moduleTitle=Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5171221e521f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737743, encodeId=0b811e37743d3, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=替吉奥胶囊联合顺铂治疗晚期胃癌的临床疗效, objectType=article, longId=220679, objectId=05a82206e9ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05a82206e9ee, replyNumber=0, likeNumber=72, createdTime=2022-05-28, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05a82206e9ee, moduleTitle=替吉奥胶囊联合顺铂治疗晚期胃癌的临床疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05a82206e9ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737734, encodeId=0e7a1e37734d5, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Clin Cancer Res：抗集落刺激因子单克隆抗体Lacnotuzumab联合吉西他滨-卡铂治疗三阴性乳腺癌的疗效, objectType=article, longId=218488, objectId=28cf21848858, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28cf21848858, replyNumber=0, likeNumber=70, createdTime=2021-12-07, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28cf21848858, moduleTitle=Clin Cancer Res：抗集落刺激因子单克隆抗体Lacnotuzumab联合吉西他滨-卡铂治疗三阴性乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28cf21848858)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737737, encodeId=482d1e377376d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Cancer Commun：紫杉醇脂质体+顺铂vs 吉西他滨+顺铂一线治疗局部晚期或转移性肺鳞状细胞癌的疗效：多中心随机对照研究, objectType=article, longId=219626, objectId=89d3219626c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89d3219626c9, replyNumber=0, likeNumber=70, createdTime=2022-09-05, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89d3219626c9, moduleTitle=Cancer Commun：紫杉醇脂质体+顺铂vs 吉西他滨+顺铂一线治疗局部晚期或转移性肺鳞状细胞癌的疗效：多中心随机对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89d3219626c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737751, encodeId=06941e37751a1, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Front Oncol：SMART+顺铂（CDDP）/S1治疗老年食管鳞状细胞癌（ESCC）患者的疗效和安全性, objectType=article, longId=221107, objectId=ae7022110e3c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae7022110e3c, replyNumber=0, likeNumber=70, createdTime=2022-03-19, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae7022110e3c, moduleTitle=Front Oncol：SMART+顺铂（CDDP）/S1治疗老年食管鳞状细胞癌（ESCC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae7022110e3c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737795, encodeId=63a01e3779513, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=顺铂、卡铂、奥沙利铂......5种铂类药物有何区别？超全盘点！, objectType=article, longId=726498, objectId=feefe264980b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=feefe264980b, replyNumber=0, likeNumber=87, createdTime=2023-02-08, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=feefe264980b, moduleTitle=顺铂、卡铂、奥沙利铂......5种铂类药物有何区别？超全盘点！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=feefe264980b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737764, encodeId=78041e37764a9, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Clin Cancer Res：Adavosertib联合各种化疗药治疗原发铂耐药的卵巢癌、输卵管癌、腹膜癌, objectType=article, longId=293566, objectId=93972935663a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93972935663a, replyNumber=0, likeNumber=74, createdTime=2022-11-24, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93972935663a, moduleTitle=Clin Cancer Res：Adavosertib联合各种化疗药治疗原发铂耐药的卵巢癌、输卵管癌、腹膜癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93972935663a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737736, encodeId=2acd1e377369f, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Urol：哪类肌层浸润性膀胱癌患者从铂基新辅助化疗中获益很大？, objectType=article, longId=219531, objectId=8aec2195316c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8aec2195316c, replyNumber=0, likeNumber=80, createdTime=2021-10-31, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8aec2195316c, moduleTitle=J Urol：哪类肌层浸润性膀胱癌患者从铂基新辅助化疗中获益很大？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8aec2195316c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737786, encodeId=97441e37786ad, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, objectType=article, longId=301205, objectId=7d6a3012059f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d6a3012059f, replyNumber=0, likeNumber=80, createdTime=2022-09-11, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d6a3012059f, moduleTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d6a3012059f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737787, encodeId=44481e377878d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=重磅！FDA新批准：新辅助疗法纳武利尤单抗联合铂类用于治疗早期非小细胞肺癌, objectType=article, longId=301277, objectId=a25e3012e7e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a25e3012e7e9, replyNumber=0, likeNumber=72, createdTime=2022-07-15, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a25e3012e7e9, moduleTitle=重磅！FDA新批准：新辅助疗法纳武利尤单抗联合铂类用于治疗早期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a25e3012e7e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737724, encodeId=e0dd1e37724dc, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Eur J Cancer：铂类+5-氟尿嘧啶+西妥昔单抗可作为中国复发/转移性头颈鳞癌患者的新一线治疗方案！, objectType=article, longId=216219, objectId=7cde216219cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cde216219cc, replyNumber=0, likeNumber=73, createdTime=2022-05-06, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cde216219cc, moduleTitle=Eur J Cancer：铂类+5-氟尿嘧啶+西妥昔单抗可作为中国复发/转移性头颈鳞癌患者的新一线治疗方案！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cde216219cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737774, encodeId=569d1e3777474, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Eur Arch Otorhinolaryngol：小儿铂诱导耳毒性的长期听力随访, objectType=article, longId=295423, objectId=91d2295423f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91d2295423f5, replyNumber=0, likeNumber=76, createdTime=2022-11-07, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91d2295423f5, moduleTitle=Eur Arch Otorhinolaryngol：小儿铂诱导耳毒性的长期听力随访, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91d2295423f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

铂

2020-05-29

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Clin Cancer Res：Adavosertib联合化疗治疗铂耐药的卵巢癌、输卵管癌及腹膜癌的效果

2022-07-02

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

JAMA Netw Open：中肿麦海强教授团队证实奈达铂为基础的同期放化疗可作为II-IVB期鼻咽癌患者的有效治疗方案

2022-09-20

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

J Clin Oncol：卡培他滨加用奥沙利铂可作为II-III期结直肠癌的替代辅助治疗

2023-04-03

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

BMC Cancer：顺铂加依托泊苷(EP) vs卡铂加依托泊苷(EC)治疗广泛期SCLC的疗效和安全性

2022-03-20

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

JAMA Oncol：紫杉醇+顺铂+卡培他滨诱导化疗可改善晚期鼻咽癌患者的生存预后

2022-11-16

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

奥沙利铂联合多烯磷脂酰胆碱对胃癌细胞增殖影响研究

2022-01-14

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Ther Adv Med Oncol：依维莫司联合顺铂治疗晚期肺外神经内分泌癌(EP-NEC)的疗效和安全性

2023-01-09

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌

2021-12-22

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌

2022-10-11

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

替吉奥胶囊联合顺铂治疗晚期胃癌的临床疗效

2022-05-28

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Clin Cancer Res：抗集落刺激因子单克隆抗体Lacnotuzumab联合吉西他滨-卡铂治疗三阴性乳腺癌的疗效

2021-12-07

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Cancer Commun：紫杉醇脂质体+顺铂vs 吉西他滨+顺铂一线治疗局部晚期或转移性肺鳞状细胞癌的疗效：多中心随机对照研究

2022-09-05

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Front Oncol：SMART+顺铂（CDDP）/S1治疗老年食管鳞状细胞癌（ESCC）患者的疗效和安全性

2022-03-19

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

顺铂、卡铂、奥沙利铂......5种铂类药物有何区别？超全盘点！

2023-02-08

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Clin Cancer Res：Adavosertib联合各种化疗药治疗原发铂耐药的卵巢癌、输卵管癌、腹膜癌

2022-11-24

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

J Urol：哪类肌层浸润性膀胱癌患者从铂基新辅助化疗中获益很大？

2021-10-31

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性

2022-09-11

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

重磅！FDA新批准：新辅助疗法纳武利尤单抗联合铂类用于治疗早期非小细胞肺癌

2022-07-15

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Eur J Cancer：铂类+5-氟尿嘧啶+西妥昔单抗可作为中国复发/转移性头颈鳞癌患者的新一线治疗方案！

2022-05-06

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Eur Arch Otorhinolaryngol：小儿铂诱导耳毒性的长期听力随访

2022-11-07

科室
- - 订阅+
  - 更多科室
工具
服务